AstriVax, a Leuven, Belgium-based provider of a plug-and-play vaccine platform, received a grant of €2.5M.
The government grant was awarded by Flanders Innovation & Entrepreneurship (VLAIO).
The company intends to use the funds to advance its technology and its vaccine platform.
Founded in 2022 and led by Hanne Callewaert, Ph.D., CEO, AstriVax develops novel prophylactic and therapeutic vaccines that have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases.
The non-dilutive financing builds upon the €30m seed financing raised in 2022. AstriVax is supported by V-Bio Ventures, Fund+, Flanders Future TechFund managed by PMV, Thuja Capital, Ackermans & van Haaren, OMX Europe Venture Fund (Mérieux Equity Partners and Korys), BNP Paribas Fortis Private Equity, and the KU Leuven Gemma Frisius Fund.
FinSMEs
30/05/2023